To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
Languages
Recent
Show all languages
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
.
Leo
Newton
Brights
Milds

From Wikipedia, the free encyclopedia

Trafermin
Clinical data
Trade namesFiblast
Other namesCAB-2001; Recombinant human basic fibroblast growth factor; rhbFGF; 2-155-Basic fibroblast growth factor (human clone lambdaKB7/lambdaHFL1 precursor reduced)
Routes of
administration
Topical (spray)[1]
ATC code
Identifiers
CAS Number
PubChem SID
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC764H1201N217O219S6
Molar mass17122.67 g·mol−1

Trafermin (brand name Fiblast), also known as recombinant human basic fibroblast growth factor (rhbFGF), is a recombinant form of human basic fibroblast growth factor (bFGF) which is marketed in Japan as a topical spray for the treatment of skin ulcers.[2][3][1] It is also currently in preregistration for the treatment of periodontitis.[2][4] As a recombinant form of bFGF, trafermin is a potent agonist of the FGFR1, FGFR2, FGFR3, and FGFR4.[5][6] The drug has been marketed in Japan since June 2001.[citation needed]

References

  1. ^ a b Han SK (15 September 2015). "Growth Factor Therapy". Innovations and Advances in Wound Healing. Springer. pp. 206–. ISBN 978-3-662-46587-5.
  2. ^ a b "Trafermin - Kaken Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
  3. ^ "Trafermin". Drugs.com.
  4. ^ Kitamura M, Akamatsu M, Kawanami M, Furuichi Y, Fujii T, Mori M, et al. (April 2016). "Randomized Placebo-Controlled and Controlled Non-Inferiority Phase III Trials Comparing Trafermin, a Recombinant Human Fibroblast Growth Factor 2, and Enamel Matrix Derivative in Periodontal Regeneration in Intrabony Defects". Journal of Bone and Mineral Research. 31 (4): 806–814. doi:10.1002/jbmr.2738. PMID 26547659.
  5. ^ Barnard JA, McHugh KM (10 May 2006). "Growth Factors in the Gastrointestinal Tract". In Barrett KE, Ghishan FK, Merchant JL, Said HM, Wood JD (eds.). Physiology of the Gastrointestinal Tract. Academic Press. pp. 216–. ISBN 978-0-08-045615-7.
  6. ^ Hamid M. Said (4 July 2012). Physiology of the Gastrointestinal Tract, Two Volume Set. Academic Press. pp. 235–. ISBN 978-0-12-382027-3.

External links

This page was last edited on 19 February 2024, at 22:22
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.